MedTrace Logo

The Use of Faster Acting Aspart in Type 1 Diabetes Patients

NCT04711382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 438

Last updated 2021-01-15

No results posted yet for this study

Summary

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

Conditions

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • University Hospital, Antwerp

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2020-12-14
Completion
2021-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711382 on ClinicalTrials.gov